Kathleen D. Scott, Chief Financial Officer at ARS Pharmaceuticals, Inc. (SPRY), sold 12,500 shares at $16.00 ($200K) on 2024-08-20, disclosed to the SEC on 2024-08-21.
Scheduled sale ($200k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| SPRY | SELL | 2025-05-22 | $705K | — | Filing → |
| SPRY | SELL | 2024-10-17 | $200K | — | Filing → |
| SPRY | BUY | 2022-12-01 | $51K | — | Filing → |